Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-10-01

Clinical Trial Update: A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine [Phase 2]

View source ↗

Summary

Phase 2 trial update for bryostatin in moderately to severely Alzheimer’s disease patients not on memantine has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bryostatin (Bryostatin-1)

Snippet

Sponsor: Neurotrope Bioscience, Inc. | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-10-01